Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.In addition to reporting an increase in its revenues, life sciences company CalbaTech has outlined its expectations for LifeStem Inc, its subsidiary that is focusing exclusively on the emerging adult stem cell market.
Subscribe to our email newsletter
According to the company, the market for stem cell technology is currently $500 million, and has been estimated to grow to $30 billion by the year 2010 due to the growth of new cellular therapeutics as well as clinical applications.
LifeStem’s strategy is to leverage CalbaTech’s infrastructure of companies to obtain a leadership position in the emerging stem cells arena and become a preferred provider of adult stem cells to the clinical researcher as part of a comprehensive package of stem cell based services.
The company is focused on providing a stem cell banking service to affluent individuals; providing services and technologies to facilitate the efficient acquisition and delivery of purified adult stem cells to the research market; developing delivery devices for clinical applications, and developing clinical applications of specific stem cell based therapies.